Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Hello everyone. Welcome to this third quarter result update from Orexo AB. It's what in Sweden is called a 'Super Thursday' in terms of reports. So, those of you who have chosen to dial into our call, I appreciate that a lot. As I understand, we are in tight competition with other companies here at 2:00 Swedish time. I am joined today by Fredrik Järrsten, who will take us through the details in the financial development, where I will give a business update and also close out our discussion on future value drivers. So just to start the presentation or give a little brief, I think we call the presentation a quarter with setbacks and achievements. The achievement this quarter, I believe, is primarily centered around Zubsolv. Even though when you look at the headlines and at the net revenues, you might think, ‘Okay, this is dropping compared to last year and the previous quarter.' But I think, looking behind the data we actually have, we're quite pleased to see where we are headed with Zubsolv, and in particular, when breaking down different segments where we see growth in our most important segment. And we also see a stabilization in the soft-sell demand. So that, I think, is very important as something we have been talking about for quite a while, regarding how we are looking forward to the stabilization of Zubsolv. And we actually see that from a volume perspective. Then we'll come back to why we don't really see that coming through. On the net revenue side, the main setback involves OX124 and its approval process. Just before the end of our Q2 report, we received a complete response letter from the FDA. We've been working during this quarter to come up with a briefing book, and it's been sent and shared with the FDA, and we now have a meeting scheduled here in November where we will receive feedback on this briefing book. I'll come back to that a little later also, but as we've gone through the details, we also recognize that we need to run some additional tests and some additional manufacturing, which is going to take some time. On AmorphOX, we are conducting a substantial number of feasibility projects with both internal assets and molecules, as well as with partners. And I have some examples in the report here of what we're doing and what are the things that we are looking for in these partnership projects. And then finally, we talk a little about what is going to happen next. And when we look into 2025, what we know is that we will have a resolution of at least one of the legal disputes, the one with Sun Pharmaceuticals on our IP. But we are also working very hard, and there's been a significant amount of expenses in this quarter also to work on the other one, which is around the subpoena and the investigation associated with the subpoena, something we would like to resolve. And then the question arises: when that certainty has been created, what are we going to do next in the company? And this is an initiative we've taken together with the board, where we're basically reviewing the entire company and asking, what is the path forward when we have these issues resolved under certain assumptions about their resolution? What we do know is that we have an R&D facility in Sweden, which has some exciting opportunities surrounding the AmorphOX platform. A lot of that is not in the direction of opioid use disorder. At the same time, we also have a commercial unit in the US where we will have a second product. I'm pretty convinced that OX124 will get to the market, although it has been delayed slightly. So we will have launched products, we'll have a bigger portfolio, and I'm also very confident that we will have a good outcome from the Sun Pharmaceuticals litigation, which will give us a long, long time left on the Zubsolv patents. What are we going to do with that? What are we going to do with Sweden to ensure that we have the resources needed to grow.
Around.
AmorphOX, but also the resources needed to launch in the US. Continue to grow the OX124 and Zubsolv businesses in the US. A little on the US commercial. So I actually think that here, in the shadows of the net revenues, there are some good developments. We have seen market growth has been down in the 2 to 3% range for a while. We saw in this quarter that it bumped up to 5%. Some of that is due to non-retail revenues, but most of it is due to the commercial segment continuing to show very strong growth. It's growing by 22% from last year. Even Medicare is growing. That is partially offset by a decline in Medicaid. But the decline in Medicaid is actually slowing. When we look from a year-over-year perspective, Medicaid continues to be the largest segment, but commercial is coming closer as we continue to see this growth gap. And that is important for us because the commercial segment is more profitable to us than both Medicaid and Medicare. And as we see growth in commercial, that will have a good positive impact long term on Orexo AB. And when we look at Zubsolv, this is actually the case; we just looked through every quarter back to 2019 when we lost UnitedHealth Group and Humana. This is the best development we have experienced year over year since 2019. Would you say it's still a negative, but it's only minus one? It is. The year-over-year is still affected by UnitedHealth Group and Humana. But when we look at the quarter over quarter, we actually see those two being completely stable and even growing a little. We do see growth in the commercial segment both year over year and quarter over quarter. And when we go into the quarter over quarter, we actually see all of the different segments are basically stable, with the Staplewood commercial, for example, being up a little, while Medicaid being down by a fraction of a percent. But all in all, we see a very stable development and also the effect of UnitedHealth Group and Humana. I think we are coming to a conclusion on that now from a volumetric perspective. Then looking ahead, we know that in Medicaid and Medicare, there is significant pressure on pricing. They are very prone to using generics, especially in Medicare. There are some new rules about pricing which have significantly affected our net revenues this quarter. And that's regarded in Medicare, called the donut hole, which is kicking in now on Zubsolv. So for us, growth in the commercial sector is really important for profitability and long-term sustainability. We continue to have excellent reimbursement in the commercial segment with access to 98% of the patients. Whereas in the public segment, Medicare and Medicaid have access to a little more than 50% with all of the published formularies for next year. They have kept Zubsolv in their reimbursement plans. We are not seeing any changes, but there will be some changes, I think, in the Medicaid and Medicare segment, which could put a little pressure on profitability. Then comes turning these volumetrics into money. What are the volume numbers you see in prescriptions? These are collected by a company called IQVIA, and are based on their inquiries with pharmacists about which prescriptions they have encountered. So there is a lot of it based on fact, but there is also both a lack and a need for them to basically fill the gap between those who are not reporting. For some reason, we go a week. So there are a level of estimates involved in this. So what's really important is of course the money coming into Orexo AB and what we are selling; we are selling to wholesalers and wholesalers then sell to pharmacies. What we have seen is that pharmacies are the best predictor of the developmental trends. It's quite stable. We don't see big variations week over week, but with wholesalers, it's basically three large wholesalers. In the US, we observe quite dramatic variations week over week and even quarter over quarter. And as those of you who have been following us for a while saw in Q1, as you can see here, the dark line represents the wholesaler sales. When that's below the lighter line, it indicates that the inventory is reduced; when it's above the lighter line, the inventory is building. That means the inventory is building at the wholesalers. And we've seen for most of this year it has been below Q2. We had a peak at the end, which essentially increased the inventory slightly. But then we saw that drop coming in Q3, and after the drop at the beginning of the quarter, sales have been slightly below the sales to pharmacies. And that means that we also in this quarter saw a decline in our inventory levels, and Fredrik will come back to that a little later in terms of how that impacts our sales. But just recall, when you look at Orexo AB numbers, I think all pharma numbers, one thing is prescriptions. That's important. Of course, the most important thing is that we see people prescribe our products to patients. Then we have to convert it into sales. And when Fredrik showed his numbers, those were actually based on reported sales. And the numbers I refer to here are these volume metrics and prescriptions, except for this picture. Then, coming into our products under development. And OX124 is of course the main thing here right now where we knew from earlier this year that we had an issue, according to the FDA, with our instructions for use. At the beginning of the last quarter, we completed a new human factor study, which was very successful. So we believe we have addressed that issue. But the FDA also raised issues concerning the technical data. We shared that at our last report, and what they are looking at is technical data related to the device and the packaging. So essentially, it's not the actual powder or the clinical effect, but rather how the device and the packaging influence the use of the product. And that means essentially that the device should operate as intended under various circumstances. And what they want us to do is to test that the device and the packaging meet the requirements. Even after being produced on a commercial scale, we at Orexo AB do not foresee that this should have an impact. But this is the request of the FDA. But it also means that we need to set up. We have set up the commercial line, but now we need to produce the batches according to the specifications of what we need to show the data that the FDA is requesting. And that is done through our third-party manufacturing partners, and we also have to get the supply of these test tubes from our device manufacturer. And as it looks right now, we have started the process and are about to finish it. We will do that at the beginning of next year. But then we need to complete the tests that they're asking for. And some of these tests basically require that we allocate time. So we need to do a test over a longer period of time to meet those specifications. We are talking to the FDA later this month, and that will give us final feedback on our progress, the tests required, and the amount of data needed. What is critically important for us is determining how much stability data the FDA requires, and over what timeframes, as this testing is already part of the original process. There is a time element included in the testing, but there could be additional requirements from the FDA, and we will need to consult with them about that. From our perspective, we haven't seen any impact on time when we're looking into the data that we have from the pilot scale, then going into the market for OX124. It is an interesting market because it was converted into an OTC market, with Narcan the lead brand being OTC, going from a prescription product to an OTC product. And what we have seen is a remarkable growth in the demand in the market. So the access to these overdose medications has become significantly broader. You can today find it in all kinds of shops across the US. And that, of course, makes it much more accessible for those who are at risk of an overdose. And I think that can explain the slowdown in the number of overdoses that we see in the U.S. Based on the feedback we have received when we've been out talking to customers or potential customers during the quarter, we do see that quite a lot of them see a need for a high dose option. And there are some examples here from a physician who says that about 30% of his patients should be considering this high dose because they are exposed to synthetic opioids. We have a firefighter who is saying, basically, we consistently have to give patients multiple doses of Narcan because they have overdosed with synthetic opioids, or they have a risk of residual overdose. That's kind of the same. Residual overdose comes when you're overdosing on a synthetic opioid, which has a much longer half-life. That means it stays in the body for a longer period of time than heroin, for example. So, our interviews with customers confirmed that there is a need, and it is closely related to this high dose. It's also related to the temperature resistance as it's a powder. We don't have a risk of freezing, which for a lot of areas addresses concerns that they have with the current products available, which are all based on a liquid form. We have seen during the quarter that our competing product, the first mover in this segment which is transitioning similar to how Naloxone went from injection to nasal sprays, has received approval both in the US and in Europe. From an Orexo AB perspective, we have engaged with the FDA, where our briefing book was accepted, and held consultations with relevant authorities in Europe, securing a confirmed regulatory pathway and clinical program necessary for approval in both the US and Europe. We do see that OX640 has a lot of advantages compared to the new entrant into the market. Nephi. It's around stability, and it's temperature resistant. We don't have any preservatives in the OX640. We have a dose conformity committee that we haven't seen in any other product in the space. So we think that there are a lot of opportunities and value for OX640. But some of the concerns that have been raised when we've been discussing with other companies are about how the powder will react in cases of allergic rhinitis. That means when you have an allergic shock, it's quite often that you will have a swelling feeling in your nose and a running nose. And we are now going to test how that will affect the participants. A small study was conducted here in Uppsala, Sweden, which essentially started on the 22nd of October, when the first six participants were dosed. We expect the completion of this study at the end of the quarter, and we will have results early next year. It's, of course, cost some money. It's about $1 million or 11 million Swedish kronor for the entire study. And that is included in the cost guidance that we've provided to the market. We have also continued discussions with partners, both on a global basis and, more recently, with regional partners as well. So it's something we are looking into: what is the best portfolio and approach moving forward with OX640? But we do believe that the new study will further strengthen the case and enhance the differentiation opportunities compared to other products in the pipeline, and the one that was recently approved. Then taking our AmorphOX platform and incorporating a few more molecules to show some of the developments we have been working on. So here, we have active projects around, for example, Epinephrine Naloxone, and we have some of the partnered projects on the right side, which are also active at the moment. Some of them are projects we have conducted to test the effects of different types of chemical structures or molecules on AmorphOX, but what we consistently observe is a very stable formulation, both in small molecule peptides and biologics. And when you see some of the biologics, particularly the vaccines we have here, which are partner projects. So a virus-like particle, which is a type of vaccine, is accentuated by what we’ve seen here; when being processed in the AmorphOX technology, we still see that the molecule works as intended. And this gives us some good insight. Um, you say it's a good reason for us to continue working with these larger molecules where we see the AmorphOX platform has a lot of value to create and to show some examples of the value that we believe we can create for potential partners. We have shown that we can formulate very sensitive APIs in various sizes. We can work with lifecycle management. So basically, when you have, for example, an injectable, you can switch to a nasal product. And that's a needle-free alternative for administration rather than injection. We can work with cost reductions because some of the big costs, particularly for large molecules, are associated with the cold chain. And here we have a few examples of some. It's not exhaustive by a long way, but these are some examples of different companies that have been working with a biomolecule. There are two vaccines that a NCI is investigating, where we can observe that each is seeking different properties. With improved stability from the product, there could be a new product opportunity. Basically, you can expand into new areas or you can work. So, with a completely new product, you could also work with new indications. So basically, take your existing indications and work with them in a new way. For example, when you move from injectable to nasal administration, speed of onset is important. For example, for the partner we had with an NCI project, patient convenience is important. And of course, intellectual property is very important. And we have patents for AmorphOX in different molecules from 2039 to 2044. And then when you start working with a partner, that could very well result in new patents emerging from that collaboration, followed by moving to the finance and legal update. And we'll leave the work to Fredrik, please.
Thank you, Nikolaj. So, going to page 16. So we look at our revenue, and if we start by looking at the top part of the page, you can see that our total revenue in Q3 amounted to approximately 136 million. And of that revenue, obviously, Zubsolv within the US commercial market is the main contributor with 131 million for the quarter. That's down year over year with 6.7%, following a negative impact of 5 million from a weaker USD FX rate and a decline in demand from the public part of the open segment as well as within Humana. Now, this was partly offset by a favorable payer mix following a price increase in January this year. In relation to HQ and pipeline revenues, we had substantially lower Abstral royalties for the quarter due to a retroactive one-time adjustment of Q3 and Q4 2023 royalties, which in turn is due to adjustments in partner-reported royalties. Now, this adjustment is partly offset by an accrual for Q3 royalties, but the net effect on Abstral royalties amounted to -1.4 million as of Q4. There will be no more retroactive adjustments of this kind, but the royalties will continue. As we talked about last quarter, they will gradually decline as we now see agreements for individual countries expire. Also commenting on Zubsolv ex-US revenues will show a decline from last year. But what we see here is a shift from low-margin product sales of tablets to our partner Core Healthcare towards increasing high-margin royalties from Accord on their own sales of Zubsolv. We expect this trend to continue, potentially offsetting the margin effect from lower App Store royalties. If you look at Zubsolv specifically in Q3 compared to Q2, you can see in the waterfall graph on the bottom part of the page that the decrease in net revenues of 11.4% is, to a minor degree, a consequence of reduced demand expressed in SEK, and is solely evident in the public segment from quarter to quarter. We can now also see stabilized demand in UnitedHealth Group and Humana, as Nikolaj Sørensen mentioned the main reasons for the decline from a strong quarter two primarily being a higher inventory destocking effect that was almost 8 million SEK, and as well as a negative effect quarter over quarter of 3 million. That is somewhat offset by a favorable payer mix. In conclusion, you can also see in the graph in local currencies, Zubsolv net revenue decreased by 9.4% between the quarters. Going to the next page, our P&L, we have a marginally negative EBITDA for the third quarter: 0.7 million negative. The main reason is the 20 million SEK reduction in net revenues. But doing the exercise that we usually do, adjusting for legal and other non-repeating costs, that would actually imply an EBITDA of approximately 9 million for nine months. EBITDA is positive at 20 million SEK. So that gives us confidence that we can reaffirm the outlook of reaching a positive EBITDA for the full year. On the positive side, we have been able to maintain our high gross margin of 86% from last year, and the majority of the 20 million SEK in cost of goods sold is related to US commercial. If we look at our operating expenses in Q3, they are significantly lower by 15% compared to last year, with especially lower administrative expenses related to digital mental health products in US commercial and lower R&D costs due to reduced expenses for OX124 and digital mental health product development. These lower expenses were partly offset by higher expenditures for OX124 launch preparations and operations in the US commercial sector, as well as increased legal costs for the DOJ investigation. The US dollar weakened in the third quarter compared to last year, and the total effect on EBIT was a negative 8 million SEK. In summary, operating expenses came in at 138 million SEK. Now, the EBIT contribution from our US commercial segment was 25 million for the quarter, which is a margin of 19.3%. And finally, in financial items, we had higher bond loan costs of 13 million due to higher interest expenses for the new bond. We also have an unrealized FX impact of 2.9 million on cash held in US dollars.
Oh.
Yeah. Going to the next page. Cash flow. We can see that liquid funds, cash, and cash equivalents amounted to 115 million at the end of Q3, a decrease of 25 million from Q2. We should not forget, though, that we have 30 million SEK in exposure in our own bonds as a potential source of funds. So we have cash flow from operating activities of -13.4 million that was primarily impacted by negative operating earnings, which in turn was affected by these legal and other non-recurring expenses of 9 million. We paid interest of 13.7 million for the new bond loan, which was 3.6 million higher than last year and 20 million higher year-to-date. Then, adjustments for non-cash items that include changes in provisions in the US. And this quarter, there was a negative effect of 13.6 million from these changes in provisions, following the timing of payments or payer rebates. Operating cash flow was also affected by a positive change in working capital of 8 million. Total cash flow for the period ended up at -20 million, and then adding an effect on cash of -4.7 million. Thus, that adds up to a decrease in cash of $25 million. And then the financial outlook we show here on this page, the outlook for 2024 that we put up for the first time in the Q4 2023 report, stating that we expected market growth of 2 to 5% of net sales, in line with the 2020 forecasts in US dollars, and OpEx below 530 million along with positive EBITDA. Now, based on the current circumstances, we maintain our guidance for 2024 on these metrics. We do see some risk to the revenue guidance due to inventory adjustments we've seen among the wholesalers affecting the entire market. In addition, a potential settlement of the ongoing DOJ investigation and increased R&D expenses related to the resubmission of OX124 may affect our cost projections and financial results. And with that, I hand it over to Nikolaj for the legal updates.
Thank you very much. And maybe just to give a short-term outlook, as I mentioned in the CEO comments, we do expect that this negative effect on inventory will not be there in the fourth quarter. Normally, we do see the opposite in the fourth quarter. That means that we see an increase in the inventory with the wholesalers. So, we anticipate that the net effect you observed in the waterfall graph between Q2 and Q3 will actually reverse in the fourth quarter. And that will, of course, have a positive effect on the financial results all the way down to the cash flow as well. So this third quarter was a little problematic from that perspective. But underlying, the most important aspect for us is to see that Zubsolv remains stable over time. It will have a positive impact on inventory levels. It will have a stabilizing effect on inventory levels. And of course, when we see the commercial segment growing, that could have a positive effect on profitability. On the legal update, there's not much to say except that we would, of course, like to see these results as soon as possible. And we have worked in particular on the second part here, the US government agency investigations related to marketing. We have been working with our lawyers to see if there are pathways to a resolution, which is very much out of our control, but we are actively working to see if there is a solution for the Zubsolv patent dispute. We have not received a date for the federal hearing. I know we were anticipating that this would happen this year. We have not heard about that. We just saw the dates last night for December, and we were not on the schedule for that month either. We would like to see a solution on this one as well, so there could be opportunities for us to find a resolution ahead of time. But we are very confident in the strong decision that we see in the District court and that we would also have a favorable outcome in federal court. But of course, in all of these legal processes, there are risks of an unfavorable outcome. Just rounding up with where we are right now moving forward, it is, of course, very important for us to see growing revenues. It is a disappointment that the launch of OX124 has been delayed because that would be a good growth driver for the revenues. We, however, are encouraged by seeing the stabilization and demand with Zubsolv. It's very important next year to see growth in the commercial segment because we also anticipate some adjustments on the negative side, particularly in the Medicare segment. Next year, we are looking to continue to work. What is it? The core of what we do in the US is to ensure that our products have access, and we are actively working to see if we can expand access to Zubsolv to more patients. It is quite remarkable that since 2019, when we saw a big inflow of generics, we have actually managed to increase our market access for Zubsolv from about 30% to more than 50%. So there are pathways, but it's not cheap when you're improving in public. But we do think that the volume coming in is important for the company long term, despite being under higher rebates. And then we have the AmorphOX platform. These processes do take time, but what I'm encouraged by is to see that we have more and more companies that we work with on different early stage projects. The big thing, of course, and proof of concept from a financial perspective, is when we can convert these early stage projects into actual license agreements or large-scale development programs. What I will say is that for several of these projects we've been running, we have actually received payments. So we've received payments for some of the work that we're doing, which is covering most, if not all, of our expenses. With that, I will open up for questions. And thank you for listening to me and Fredrik.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Claus Palin from Carnegie. Please go ahead.
Thank you. And thank you for taking my questions. Uh, my first question would be related to OX124 and your next scheduled meeting in November with the FDA. Does that include a discussion about when to refile and if you need to await the testing of the commercial batches, or are there other topics you are going to discuss as well?
To address that question, the meeting with the FDA basically involved our receipt of a complete response letter, and we have responded to all of the items in the letter. Several of them we believe we have already addressed and have results. And then we have one. We can say there are more open questions. And that's around the technical data that I referred to. The meeting with the FDA will give us a guideline of what data they would require before we can submit. And that will, of course, be driving the timeline for when we can submit this complementary data. You can say the file is still open with the FDA, so we don't have to refile, but we have to complement our existing file. So, the important output of that meeting is determining how much testing we need to do. And in particular, do they need more stability data? That means we need to wait a certain amount of time to conduct new tests under specific conditions. Or can we submit immediately after completing the initial tests?
So, I interpret that you don't want to give any sort of guidance on when OX124 could be approved. At this point, we should await this meeting then.
I think there are two drivers of the approval timeline. So one factor is when we can submit the complementary data. As I said, we expect to begin manufacturing in the early part of next year. Then we need to do the testing, which is time consuming because it is meticulous. There are a lot of preconditions that need to be met. We need to test with a certain time or after a specific time, so it is not something that can be quickly done in the laboratory. You need to conduct activities between manufacturing and before we can start the testing. So that one, we expect to do more in the second quarter of next year. And then, depending on how smoothly it works, that will guide when we think we are ready to submit. If the FDA comes and requests even longer data, then we have to redo the testing after what you call stability. So if it's been on the shelf for a period of time, then that could impact the testing. We don't see that as necessary, but it is the FDA who is making the decision on the timing. So that's the first thing. And then when the FDA receives it, they need to make a decision on what review time they will allocate to it. Is it two months, or is it six months? And we won't know that before we have submitted the data.
You can say the file is still open with the FDA, so we don't have to refile, but we have to complement our existing file.
Perfect. And just if you could comment anything about the additional costs this testing could lead to.
Uh, we haven't.
We haven't put out a guidance. I think most of the expenses will occur this year, which is within the guidance we have already provided. We haven’t issued guidance for that aspect yet. And I think we would need to see what the FDA is coming back with, but maybe I can say as much. It's over the full period. Maybe around 20 million.
Okay, perfect. Um, then my next question would be regarding OX640 and the study that you recently initiated; how important is this study to close the partnering deal? Would you say?
So?
So maybe just one thing. To be clear, Klaus, there have, of course, been expenses for OX124 this year as well. So when we talk about the additional cost, I still believe that we can see improved costs next year even with those extra costs, but with OX640 I. So this has come up in most of the talks. Those of you who have been following the space of epinephrine, remember, the FDA Advisory Committee was putting a lot of focus on Nephi's request on the allergen challenge and the effect of that. So it has come up in virtually all partnering meetings. Whether that will trigger a signature is very hard to say, because the partnering discussions depend on many factors that are out of our control, including privatizations by the partners. We have seen management changes in one of the leading companies we were working with, which essentially put a halt to the process. So there are factors that are completely out of our control. So to sit here and say, 'Okay, when we have that data, if it's successful, we will have an agreement.' I can't do that. But I do know that this has come up in every single discussion we have had with potential partners. So it will be important. And I think some of the data we are collecting could further strengthen the differentiation from Nephi that is already approved in the market.
And is it perhaps possible to give some sort of idea of what could be the next step if this study goes well?
The next step would. The next step would be for us to basically finalize the commercial version of the product. I mean, right now the testing is done, and you can say it's in the early clinical version, and then to move to the pivotal studies, which would be the next clinical trials that need to be done on the commercial product. So it needs to be upscaled. That means that we have to produce it in larger batches than what we have today, using larger machines than what we have used previously. And we will, of course, do that in the same supply chain that has already been established for OX124. But that would be the next step: upscaling and then initiating the start. The pivotal trials are not that many, but you need to show that your pharmaceutical product's bioavailability is equivalent to the products that are approved in the market.
Perfect.
Thank you. And my last question then is related to AmorphOX. You seem quite upbeat, I think, in the report about this platform. If you just, uh, I mean, from reading your CEO comment, you're alluding to the fact that you are starting new studies. Um, how many collaborations do you have running at the moment? Is it possible to give us some sort of idea?
Uh.
We haven't disclosed that, but I can say the number of companies we've been working with is more than what we have on paper right now. And then it depends on what you call a collaboration, because we have companies that we have a co-project with where we're basically together looking at how it works in different molecules. We have those who come to us with a molecule to present; however, we have not disclosed this information. But I can say that the total amount is more than what we have shown in the picture.
Okay, perfect.
Thank you so much.
The next question comes from Sameer Devani from Orix Securities. Please go ahead.
Hi, guys. Thanks for taking my question. Um, it was alluded to in your comments within the report. You've alluded to a broader strategic review of the business next year. So I'm just wondering, in light of that, does that impact how you're thinking about potentially partnering with OX640, presumably? Part of that review will look at things like spinning off AmorphOX into a separate business, in which case it would seem that having OX640 as part of that spin-off would be wiser. So is it fair to assume that the review will be done before the conclusion of any partnering discussions? Thank you.
Uh.
I would say that if the right partner comes, we will proceed with that partnership. I think that will be an important factor in this. But of course, it has an impact on, perhaps, partnerships which are less attractive. Um, and I would just say we will start a process to see how we can make the different parts evolve in the best possible way, both for our shareholders and also for the patients in the end and for the opportunities around AmorphOX. We have not locked ourselves into any solution, but I think there are various opportunities available. We could basically be looking at all the opportunities. But one thing that is certain is that one of the main drivers is where we think we can create the most value long-term for the shareholders in such a process. So, I think for all the different projects, we have to consider that carefully. I think the main trigger for this is that as long as we have the uncertainty around Zubsolv, particularly regarding the patent litigation, it doesn't really make sense to start a broader project because the risks are not fully defined. For someone who's not involved in the process, it's very challenging to comprehend the risks and opportunities in such a patent litigation. So when you have that certainty, that is a good time to go back and ask, why? How do we ensure that we have the best platform for our US opioid use disorder portfolio to evolve, grow, and meet more patients? It's very clear. Orexo AB today is subscale; with only one product in the pipeline, it is not efficient from a market and commercial perspective. And similarly, how do we ensure that AmorphOX can actually develop some of the projects? And I think OX640, there's nothing that has happened during the last half year that suggests this product lacks a fantastic opportunity in the market for Epinephrine, despite the approval of NFI, which of course increased the competition. But it also removes a lot of the risk that has been present in the regulatory pathway for these products. And we know that our products have a lot of advantages compared to that product when we come to market with it. So I think OX640 is a very important project for the company. If we find the right partner, we will of course proceed with that. I think that will take away a lot of risk and give us an opportunity to generate revenues. If it's something that is less attractive. That could be a factor in the strategic review.
And then my final.
My question is on the commercial manufacturing you’re now conducting for OX124; you mentioned it may require some stability data. And typically that's correct, am I right? That's typically 12 months that the FDA requires. So would that potentially delay the filing until 2027 or 2026, if that's the case?
I, uh.
I sincerely hope it's not 12 months. We have not had that on the table. Um, I think this is not related to the powder. If it had been the powder. I think you're right. With 12 months, this relates to the functionality of the device, as the device is already on the market with a different product. The FDA is quite aware of the functionality, and of course there could be some effect of the device and the powder, but we can't see what that would be. We have a lot of stability data on the device and the secondary package or the tube, where we have the device from our pilot scale, and we have not seen any effect of aging from that. We don't expect that to happen, but it is the FDA. In the end, it's up to their decision. But this is definitely not our going-in assumption.
Okay. Thanks very much. Nikolaj. Thanks.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and for the closing comments.
Thank you. We have also received some written questions, and the first question I have received here is about the pricing power for Zubsolv. It's about how sensitive volume and price are. And if we believe that revenues can be increased through pricing also in Q4, we cannot increase the prices within the quarter. What has an impact is what we call the payer mix. So if we see more growth in the commercial segment where we have less rebate, that will have a positive effect on pricing. If we see more growth in Medicare and Medicaid, that would have a negative effect on pricing. Right now, the trend is that the commercial segment is growing, and Medicaid for Orexo AB is quite stable, even if the market is dropping. But that can change quarter over quarter. The next normal pricing opportunity is in the beginning of next year, and that is something that our US colleagues are looking at at the moment. What kind of potential price increase do they see that is possible or should be considered for next year? And then there's a comment regarding a going concern update in your report. And then, could you kindly comment on this. Have you established a controlled balance sheet? And what is the question? We have not established a controlled balance sheet. Our going concern is related to the equity. On a group level, we don't have it, and our equity at the parent group level, which is what you're looking at in Sweden, is positive. But we have, of course, discussed with the board. We're examining our financials and see that our cash position is enabling the company to continue for the next 12 months. And so we've talked about here, we do see a lot of improvement opportunities. From a cost perspective, we hope to see significant progress. Also in business development, which could support the business. But as a prudent comment, we included this in our discussions about the going concern. I know, Fredrik, do you have any further comments on this?
No, I mean, that's correct. Um, we conclude that this report is prepared on the assumption of going concerns. So, that was the main message that we wanted to convey with this comment.
So, we have a comment here stating that you are working on opportunities to strengthen the equity of the company, while also giving some hints about the structural changes that could occur. Can you talk a bit about this and be more concrete on what kind of measures to consider? What I can say is that we have started the process and we think again that the clarity on the legal processes, in particular the Sun Pharmaceuticals patent litigation, is a trigger point where we should. I think taking the responsibility as management and board of directors to review what is the right path forward. And in that, we think that strengthening the equity of the company can come from both improving the results. So you essentially achieve better results within the company. And that could come through cost-cutting measures. So that is one area. Another area is, of course, looking into where we would. Business development. What kind of structure are we looking for in the business development phase that could help us and that could have an impact on how you design these business development initiatives. Looking at the equity position and then of course we have opportunities all the way to one of the. Opportunities to strengthen the way we can work with either our R&D function or our US business by other types.
Of partnering.
Partnering with other companies. And then, of course, as always, we also have to look continuously at the capital structure of the company to see if this is optimal for the operations we have. And that involves exploring different financing opportunities. So we have not locked ourselves into anything. But as we are approaching, we believe some resolution in at least the largest legal process on our minds is the Sun Pharmaceuticals litigation. Then that is a good trigger point. But of course, we would also like to have clarity on the other legal process, which would be another major input into such a process for the company. With that, we have not received any further questions, and I thank you for taking your time today on this very busy Thursday from a reporting perspective, and I wish you a great day. Thank you very much. Goodbye.



















